Norwood, MA (PRWEB) July 30, 2012
BioPharm Insight™, published by Infinata, covered the Alzheimer’s Association International Conference (AAIC) held in Vancouver earlier this month and found a significant focus on early intervention. In exclusive interviews, experts at the conference noted that disease modifying drugs must be administered even before symptoms appear in order for a demonstrable effect to be seen.
The future success of disease modifying candidates bapineuzumab and solanezumab was a topic of debate as some investigators interviewed by BioPharm Insight did not consider these drugs to be top contenders in the initiative to assess the hypoth¬esis of pre-symptomatic therapeutic intervention.
On the heels of the AAIC, Pfizer announced that bapineuzumab Phase III top-line results indicated the drug was not clinically effective in mild-to-moderate Alzheimer’s patients who are carriers of the ApoE4 gene. Top-line results from the bapineuzumab non-ApoE4 carrier trial as well as the solanezumab trial are eagerly awaited over the next few weeks.
Other highlights from the AAIC report include:
About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides clients with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.
About Infinata, Inc.
Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.